必治妥施貴寶

原文：Bristol Myers Squibb｜最近更新：2026-10-23

原文名稱
Bristol Myers Squibb
縮寫
BMS
類型
藥廠
國家
美國
主管領域／業務範圍
藥品研發製造，PD-1免疫檢查點抑制劑Opdivo（nivolumab）原廠

關鍵人物

—

相關政策

—

相關藥品

Opdivo、Zenbexus、iza-bren

涉及事件

Keytruda與Opdivo專利懸崖：2028年專利到期與生物相似藥進入前景、AstraZeneca與Bristol Myers Squibb傳出近4000億美元合併早期談判，消息人士後否認、Replimune溶瘤病毒療法Tudriqev（RP1）併用Opdivo獲FDA加速核准治療晚期黑色素瘤、FDA加速核准BMS首個CELMoD藥物Zenbexus（iberdomide）併用daratumumab治療多發性骨髓瘤、Biokin/BMS雙特異性ADC iza-bren中國Panku-Lung01第三期肺癌試驗期中分析達標、台灣食藥署核准Opdivo（nivolumab）可切除非小細胞肺癌新輔助併化療、術後輔助單藥治療新適應症、FDA核准Curium的BEXLUTRY，成為首個對標Novartis Lutathera的放射性配體等效藥、BMS旗下RayzeBio之RYZ101三期ACTION-1試驗期中分析達主要療效指標、美國醫院協會（AHA）等對HHS/HRSA 340B藥品回扣試辦計畫（第二版）提起訴訟

關聯關係

關係建立日期強度確定程度證據來源補充說明
阿斯利康 → 進行併購2026-08-02弱推論AstraZeneca said to have explored Bristol Myers merger媒體報導雙方近月曾就近4000億美元合併進行早期階段談判，雙方均未證實，關係強度標記為弱、確定程度為推論
參與 → AstraZeneca與Bristol Myers Squibb傳出近4000億美元合併早期談判，消息人士後否認2026-08-02中確認AstraZeneca said to have explored Bristol Myers merger為傳出合併談判之一方
執行 → Replimune溶瘤病毒療法Tudriqev（RP1）併用Opdivo獲FDA加速核准治療晚期黑色素瘤2026-08-06中確認Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battleOpdivo（nivolumab）為併用藥物原廠，配合Tudriqev共同執行核准之併用療法
執行 → FDA加速核准BMS首個CELMoD藥物Zenbexus（iberdomide）併用daratumumab治療多發性骨髓瘤2026-08-13強確認U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First RelapseBMS為Zenbexus(iberdomide)藥證申請人，取得FDA加速核准
達成協議 → Biokin/BMS雙特異性ADC iza-bren中國Panku-Lung01第三期肺癌試驗期中分析達標2023-12-01強確認Biokin bispecific ADC iza-bren hits goal in China lung cancer trial, boosting case for BMS' global testBMS於2023年末授權取得iza-bren全球開發權利，潛在82.4億美元交易（含8億美元首付款），負責全球對應試驗Izabright-Lung01
合作 → 小野藥品工業2026-08-19強確認OPDIVO® Intravenous Infusion Approved in Taiwan for the Treatment of Resectable Non-Small Cell Lung Cancer with Neoadjuvant OPDIVO in Combination with Chemotherapy Followed by Adjuvant OPDIVOOpdivo（nivolumab）於亞洲多國共同開發/授權合作關係
啟動臨床試驗 → BMS旗下RayzeBio之RYZ101三期ACTION-1試驗期中分析達主要療效指標2026-10-13強確認Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio's Radiopharmaceutical Therapy, in Patients with GEP-NETsBMS子公司RayzeBio之RYZ101三期ACTION-1試驗期中分析達主要療效指標
提起訴訟 → 美國醫院協會（AHA）等對HHS/HRSA 340B藥品回扣試辦計畫（第二版）提起訴訟2026-10-21中確認Fed Judge Allows PhRMA, Drugmakers to Intervene in 340B Rebate Lawsuit與PhRMA、AbbVie、Boehringer Ingelheim共同獲准介入訴訟

更新紀錄

日期變更內容依據來源
2026-08-01首次建檔：據IQVIA報告，BMS之Opdivo將於2028年面臨專利到期，與默沙東（默沙東）Keytruda同為市場觀察焦點Oncology Innovation: 2026 and Beyond
2026-08-03補充：傳出與AstraZeneca近4000億美元合併早期談判，未經雙方證實AstraZeneca said to have explored Bristol Myers merger
2026-08-07補充：Opdivo併用Replimune溶瘤病毒療法Tudriqev獲FDA加速核准治療晚期黑色素瘤Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle
2026-08-15補充：首個CELMoD藥物Zenbexus(iberdomide)併用daratumumab獲FDA加速核准治療多發性骨髓瘤FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma
2026-08-19補充：2023年末授權中國Biokin（映恩生物，映恩生物）之EGFRxHER3雙特異性ADC iza-bren，中國Panku-Lung01第三期期中分析達PFS主要終點，強化BMS全球試驗Izabright-Lung01成功可能性Biokin bispecific ADC iza-bren hits goal in China lung cancer trial, boosting case for BMS' global test
2026-08-21補充：Opdivo於台灣獲TFDA核准可切除NSCLC新輔助併化療、術後輔助單藥治療新適應症OPDIVO® Intravenous Infusion Approved in Taiwan for the Treatment of Resectable Non-Small Cell Lung Cancer with Neoadjuvant OPDIVO in Combination with Chemotherapy Followed by Adjuvant OPDIVO
2026-10-13補充：子公司RayzeBio之RYZ101（225Ac-DOTATATE）三期ACTION-1試驗期中分析達主要療效指標，用於Lu-177治療後惡化之SSTR陽性GEP-NETs患者，為全球首個alpha-isotope標靶放射性藥物三期成功案例（另立事件BMS旗下RayzeBio之RYZ101三期ACTION-1試驗期中分析達主要療效指標）Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio's Radiopharmaceutical Therapy, in Patients with GEP-NETs

來源

標題發布日期來源機構分級可信度
Oncology Innovation: 2026 and Beyond2026-07-17IQVIA（EMEA Thought Leadership部落格）第二級中（IQVIA顧問公司觀點文件，市場規模與趨勢數據引用IQVIA Institute等自有基礎報告，部分為IQVIA自身推估；亦引用Nature Reviews Drug Discovery等同行評審文獻）
AstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed'2026-08-03CNBC第二級中（原文WebFetch回應403，本則依搜尋引擎摘要與標題轉述）
AstraZeneca said to have explored Bristol Myers merger2026-08-02Fortune（轉述Bloomberg報導）第二級高
Editor's Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea2026-08-03FiercePharma第二級高
Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle2026-08-06FiercePharma第二級高
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma2026-08-13美國FDA（官方公告）第一級高（FDA官方核准公告）
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse2026-08-13Bristol Myers Squibb（公司新聞稿）第一級高（公司官方新聞稿，惟屬企業自述，已與FDA官方公告FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma交叉驗證）
Biokin bispecific ADC iza-bren hits goal in China lung cancer trial, boosting case for BMS' global test2026-08-18FiercePharma第二級高
OPDIVO® Intravenous Infusion Approved in Taiwan for the Treatment of Resectable Non-Small Cell Lung Cancer with Neoadjuvant OPDIVO in Combination with Chemotherapy Followed by Adjuvant OPDIVO2026-08-19Ono Pharmaceutical Co., Ltd.（Ono Corporate 官網新聞稿）第一級高
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio's Radiopharmaceutical Therapy, in Patients with GEP-NETs2026-10-12Bristol Myers Squibb第一級高（公司官方新聞稿，另有OncLive、CancerNetwork等醫學媒體報導交叉確認）